The $1.2 million shot of anticancer drugs refers to CAR-T therapy, which mainly targets hematologic-related tumors such as leukemia, lymphoma, and multiple myeloma. CAR-T therapy (chimeric antigen receptor T cell immunotherapy), is a kind of immunotherapy. Simply put, it is to extract the immune T cells from the blood of tumor patients, analyze and transform them so that the transformed T cells have the effect of killing cancer cells in the patient’s body, and replicate and expand these transformed T cells and then infuse them into the patients to achieve the therapeutic purpose. CAR-T therapy is usually a method to try to use after conventional treatments (chemotherapy, targeted therapy, radiotherapy) are ineffective. Currently, the treatment has limited effect on solid tumors, and is more effective on blood system-related tumors, such as leukemia, lymphoma, multiple myeloma, etc.